{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T06:10:05Z","timestamp":1747289405286,"version":"3.40.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Proprotein convertase subtilisin kexin type\u00a09 (PCSK9) inhibitors have emerged as important therapeutic options for patients unable to achieve the low-density lipoprotein cholesterol (LDL\u2011C) target or to tolerate alternative lipid-lowering agents. The aim of this study was to investigate the efficacy of PCSK9 inhibitor treatment in tertiary routine care, by determining the percentage of patients reaching individual LDL\u2011C target levels 1 year after treatment initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Patients routinely started on PCSK9 inhibitors at our lipid clinic between 2017 and 2020 were retrospectively analyzed. Attainment of the LDL\u2011C target, utilization of follow-ups, cardiovascular events and effects on laboratory parameters were investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In this study 347 patients were included, with the majority managed in secondary prevention (94.5%). The LDL\u2011C target was achieved by 44.9% after ca. 14\u00a0months, with differences between statin users and non-users (51.0% vs. 22.7%; <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001). The median LDL\u2011C decreased from 126.00\u202fmg\/dL at baseline to 48\u202fmg\/dL (\u221261.6%; \u221277.00\u202fmg\/dL; <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) after ~2\u00a0months and to 60\u202fmg\/dL (\u221252.9%; \u221259.00\u202fmg\/dL; <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) after ~14\u00a0months. Median lipoprotein(a) levels decreased significantly from 184.0\u202fnmol\/L to 165.5\u202fnmol\/L (\u221225.9%; \u221225.5\u202fnmol\/L; <jats:italic>p<\/jats:italic>\u202f=\u20090.001) after ~2\u00a0months, whereas no effects on creatine kinase, amylase and lipase were detectable. Of the patients 15% utilized 4\u00a0follow-ups. The PCSK9 inhibitor intolerance occurred in 3.5% of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>With the effect of LDL-lowering remaining constant over 14\u00a0months, PCSK9 inhibitor treatment showed effective and sustainable LDL\u2011C lowering in a\u00a0majority of patients in secondary prevention, bringing them closer to the recommended LDL\u2011C goal, particularly those under concomitant statin medication. Treatment with PCSK9 inhibitors appears to be well-tolerated, confirming data from clinical trials in real life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-024-02402-9","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T05:02:01Z","timestamp":1723525321000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 inhibitors in real life\u2014Cardiometabolic risk management in dyslipidemic patients in Vienna"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-8156","authenticated-orcid":false,"given":"M","family":"Ferch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Sert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Fellinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Winhofer-St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2402_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"U Landmesser","year":"2018","unstructured":"Landmesser\u00a0U, et\u00a0al. 2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type\u00a09 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart\u00a0J. 2018;39:1131\u201343.","journal-title":"Eur Heart J"},{"key":"2402_CR2","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls\u00a0SJ, et\u00a0al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. Jama\u2014j Am Med Assoc. 2016;316:2373\u201384.","journal-title":"Jama\u2014j Am Med Assoc"},{"key":"2402_CR3","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber\u00a0L, et\u00a0al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical. Trial Jama\u2014j Am Med Assoc. 2022;327:1771\u201381.","journal-title":"Trial Jama\u2014j Am Med Assoc"},{"key":"2402_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2021.05.008","volume":"327","author":"NE Lepor","year":"2021","unstructured":"Lepor\u00a0NE, et\u00a0al. Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A\u00a0time course study. Atherosclerosis. 2021;327:31\u20138.","journal-title":"Atherosclerosis"},{"key":"2402_CR5","doi-asserted-by":"publisher","first-page":"131330","DOI":"10.1016\/j.ijcard.2023.131330","volume":"392","author":"S Liu","year":"2023","unstructured":"Liu\u00a0S, et\u00a0al. Effect of PCSK9 antibodies on coronary plaque regression and stabilization derived from intravascular imaging in patients with coronary artery disease: A\u00a0meta-analysis. Int J Cardiol. 2023;392:131330.","journal-title":"Int J Cardiol"},{"key":"2402_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, et\u00a0al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"2402_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047","author":"KK Ray","year":"2020","unstructured":"Ray\u00a0KK, et\u00a0al. EU-Wi de Cross-Sectionsl Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2020; https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"2402_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-021-01978-w","author":"P Siostrzonek","year":"2021","unstructured":"Siostrzonek\u00a0P, et\u00a0al. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL\u2011C goals achieved? Wien Klin Wochenschr. 2021; https:\/\/doi.org\/10.1007\/s00508-021-01978-w.","journal-title":"Wien Klin Wochenschr"},{"key":"2402_CR9","first-page":"1","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray\u00a0KK, et\u00a0al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Heal. 2023;29:1\u201311.","journal-title":"Lancet Reg Heal"},{"key":"2402_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00508-023-02221-4","volume":"135","author":"H Toplak","year":"2023","unstructured":"Toplak\u00a0H, et\u00a0al. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wien Klin Wochenschr. 2023;135:364\u201374.","journal-title":"Wien Klin Wochenschr"},{"key":"2402_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/03007995.2020.1786678","volume":"0","author":"DR Leitner","year":"2020","unstructured":"Leitner\u00a0DR, et\u00a0al. Efficacy and tolerability of alirocumab in Austrian clinical practice-results of the non-interventional PEARL-AT study. Curr Med Res Opin. 2020;0:1419\u201325.","journal-title":"Curr Med Res Opin"},{"key":"2402_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01283-w","volume":"20","author":"LT Fischer","year":"2021","unstructured":"Fischer\u00a0LT, et\u00a0al. Real-world data on metabolic effects of PCSK9 inhibitors in a\u00a0tertiary care center in patients with and without diabetes mellitus. Cardiovasc Diabetol. 2021;20:1\u201315.","journal-title":"Cardiovasc Diabetol"},{"key":"2402_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/2047487320908698","volume":"28","author":"K Kotseva","year":"2021","unstructured":"Kotseva\u00a0K, et\u00a0al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A\u00a0report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE v survey in 16\u00a0European countries. Eur J Prev Cardiol. 2021;28:370\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"2402_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","volume":"28","author":"I Graham","year":"2007","unstructured":"Graham\u00a0I, et\u00a0al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary\u2014Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart\u00a0J. 2007;28:2375\u2013414.","journal-title":"Eur Heart J"},{"key":"2402_CR15","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"\u017d Reiner","year":"2011","unstructured":"Reiner \u017d, et\u00a0al. ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart\u00a0J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"2402_CR16","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano\u00a0AL, et\u00a0al. 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart\u00a0J. 2016;37:2999\u20133058l.","journal-title":"Eur Heart J"},{"key":"2402_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00508-008-1010-9","volume":"120","author":"M Roden","year":"2008","unstructured":"Roden\u00a0M, Huber\u00a0K. Lipidprofil und therapiestatus in der sekund\u00e4rpr\u00e4vention bei hochrisiko-patienten mit klinisch manifester arteriosklerose und\/oder diabetes mellitus: Das Hospital Screening Projekt (HSP) in \u00d6sterreich. Wien Klin Wochenschr. 2008;120:558\u201365.","journal-title":"Wien Klin Wochenschr"},{"key":"2402_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00508-010-1498-7","volume":"123","author":"B F\u00f6ger","year":"2011","unstructured":"F\u00f6ger\u00a0B, Patsch\u00a0JR. LDL-Cholesterin in der Sekund\u00e4rpr\u00e4vention: Zielwert-Erreichung unter Lipidsenkern in Praxis und Spital in \u00d6sterreich (ZIEL). Wien Klin Wochenschr. 2011;123:21\u20137.","journal-title":"Wien Klin Wochenschr"},{"key":"2402_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00508-011-0057-1","volume":"123","author":"H Drexel","year":"2011","unstructured":"Drexel\u00a0H, Chazelle\u00a0F, Fauer\u00a0C, Lautsch\u00a0D, Gitt\u00a0AK. Persistent Dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events\u2014Results of the dyslipidemia international study (DYSIS). Wien Klin Wochenschr. 2011;123:611\u20137.","journal-title":"Wien Klin Wochenschr"},{"key":"2402_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s10354-013-0219-z","volume":"163","author":"M Pichler","year":"2013","unstructured":"Pichler\u00a0M, et\u00a0al. Are there differences in LDL\u2011C target value attainment in Austrian federal states? Yes! Wien Medizinische Wochenschrift. 2013;163:528\u201335.","journal-title":"Yes! Wien Medizinische Wochenschrift"},{"key":"2402_CR21","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1185\/03007995.2012.717919","volume":"28","author":"B Eber","year":"2012","unstructured":"Eber\u00a0B, et\u00a0al. Can LDL-cholesterol targets be achieved in a\u00a0population at high risk? Results of the non-interventional study ACT II. Curr Med Res Opin. 2012;28:1447\u201354.","journal-title":"Curr Med Res Opin"},{"key":"2402_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","volume":"349","author":"GG Schwartz","year":"2022","unstructured":"Schwartz\u00a0GG, Ballantyne\u00a0CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022;349:110\u201322.","journal-title":"Atherosclerosis"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02402-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:55:41Z","timestamp":1747288541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02402-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":22,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02402-9","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Ferch, C.\u00a0Sert, P.\u00a0Fellinger, A.\u00a0Kautzky-Willer and Y.\u00a0Winhofer-St\u00f6ckl declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}